Drug intelligence / Profile preview

NEXI-004

Development stage: Preclinical
Lead developer: NexImmune
Modality: Stem Cell Therapies → Cell Therapies

Overview

NEXI-004 is a stem cell therapy developed by NexImmune for the treatment of Epstein-Barr Virus (EBV) infections. It is classified as a "stem cell replacement" therapy, indicating its mechanism involves replacing or augmenting stem cells to restore immune function or combat disease. The drug is currently in preclinical development and has not yet entered clinical trials. Its primary therapeutic area is infectious diseases, specifically targeting EBV-associated conditions[1][3].

Beyond the preview

Go deeper on NEXI-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NEXI-004.

Explore the full profile